Dallas, TX -- (SBWIRE) -- 01/13/2011 -- Summary
As the pharma industry comes under increasing pressure to replenish revenues which are under threat from generic competition, there is an increased focus on technologies and trial designs which aim to maximize success and reduce development time. This report reviews the use of adaptive designs across all phases of development. Dose-ranging and seamless trials are explored through case studies of important adaptive trials. Regulation by the FDA and EMA is covered in detail. The report also reviews logistical and technological aspects of adaptive designs as well as presenting an outlook for their use in drug development.

Scope of this research

Learn how the largest companies are applying adaptive methods to improve drug development.

Identify situations in which adaptive trials could benefit drug development in your company.

Analyze the importance of adaptive trials in the context of a drug’s development program and a company’s portfolio of compounds.

Assess how the FDA’s draft guidelines on adaptive trials are influencing companies to use adaptive trials in their drug development programs.

Evaluate the providers of key skills and technologies for adaptive trials.

Research and analysis highlights

The large majority of adaptive trials currently being undertaken in the pharma industry are Phase 2 – ‘Learning’ – trials that aim to establish the most effective dose and the dose response curve. Exploratory trials may also aim to combine proof of concept with dose finding, stop early for futility or investigate biomarkers and patient subsets.

Ground-breaking research using adaptive designs with biomarkers is currently shaping the future of research in the field of oncology. The highly collaborative I SPY2 study may deliver changes to the field on a number of levels such as demonstrating the feasibility of cooperation at this level and the efficiency of the adaptive design.

Companies are learning how to implement adaptive studies in the confirmatory stages of drug development and regulators are developing their views on what is acceptable. Interaction with regulators to gain acceptance for a particular design and implementation plan, and proper documentation of decisions and actions, are a key success factors.

Key reasons to purchase this research

What is the current regulatory position on the use of adaptive trials in the exploratory and confirmatory stages of drug development?
Where and how have adaptive trials been used by the industry already? Which companies are pioneering their use?
How can adaptive trials improve drug development?
What are the costs associated with adaptive trials? Can they save money?
How can adaptive trials be used in clinical trials with biomarkers?

Advances in the Design and Regulation of Adaptive Clinical Trials
http://www.reportsnreports.com/reports/41950-advances-in-the-design-and-regulation-of-adaptive-clinical-trials.html

Market Research
http://www.reportsnreports.com/

Related Reports

Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
http://www.reportsnreports.com/reports/18440-investigating-clinical-trial-costs-comparative-analysis-of-trial.html

Patent Foramen Ovale Closure Market: Clinical Trial Outcomes to Play a Key Role
http://www.reportsnreports.com/reports/15323-patent-foramen-ovale-closure-market-clinical-trial-outcomes-to-p.html

Emerging Clinical Trial Locations: Market dynamics and the changing healthcare and regulatory environment
http://www.reportsnreports.com/reports/7389-emerging-clinical-trial-locations-market-dynamics-and-the-changi.html

Cancer Research Campaign Clinical Trials Centre – Developmental Therapeutics Review – Q4 2010
http://www.reportsnreports.com/reports/49961-cancer-research-campaign-clinical-trials-centre-developmental-t.html

AIDS Malignancy Clinical Trials Consortium – Developmental Therapeutics Review – Q4 2010
http://www.reportsnreports.com/reports/50955-aids-malignancy-clinical-trials-consortium-developmental-therap.html

AIDS Associated Malignancies Clinical Trials Consortium – Developmental Therapeutics Review – Q4 2010
http://www.reportsnreports.com/reports/50960-aids-associated-malignancies-clinical-trials-consortium-develop.html

The US Cardiac Resynchronization Therapy Market: Positive Clinical Trial Results to Boost Growth
http://www.reportsnreports.com/reports/16020-the-us-cardiac-resynchronization-therapy-market-positive-clinica.html

The Future of e-Clinical Trial Solutions - Market Forecasts to 2015, Competitive Benchmarking and Case Studies
http://www.reportsnreports.com/reports/18559-the-future-of-e-clinical-trial-solutions-market-forecasts-to-20.html

Biomarkers in Late Stage Clinical Trials: Applications, opportunities and activities of leading players
http://www.reportsnreports.com/reports/19588-biomarkers-in-late-stage-clinical-trials-applications-opportuni.html

Forecast Insight: Dyslipidemia - While the market collapses, a well designed clinical trial program pays dividends for Crestor
http://www.reportsnreports.com/reports/7194-forecast-insight-dyslipidemia-while-the-market-collapses-a-we.html

About ReportsnReports
ReportsnReports comprises of an online library of 50,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsnreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com